The World Health Organization (WHO) released its first-ever guidelines on the diagnosis and management of type 1 diabetes in adults on 14 November 2026, aiming to improve care access globally.
The publication coincides with World Diabetes Day 2026, which is centered on the theme of “Early action on diabetes.”
According to WHO estimates, approximately 9.5 million people worldwide were living with type 1 diabetes in 2025, with an additional 500,000 people receiving a diagnosis that year. Although the condition is frequently regarded primarily as a childhood issue, type 1 diabetes is increasingly affecting adults.
Standardizing Insulin Treatment and Monitoring
The agency recommends that adults with the condition receive multiple insulin injections per day, with dosages adjusted based on blood glucose levels. While human insulin is identified as an effective and appropriate option due to its generally lower cost, the guidelines note that alternative types of insulin may be utilized when necessary to ensure treatment continuity.
Regular glucose monitoring is a central component of the new recommendations. For home management, the agency supports the use of finger-prick tests or continuous glucose monitors, which utilize small sensors applied to the skin.
In instances where blood glucose testing is not available, the guidelines suggest that urine glucose testing may be considered as a solution for situations with limited diagnostic tools, rather than as a preferred alternative to standard methods.

Global Targets for 2030
The publication of these first guidelines supports the WHO’s broader objective to ensure universal access to affordable insulin and self-monitoring tools by 2030. To facilitate implementation, the organization plans to provide countries with practical tools and guidance for tracking progress in their respective health systems.
This focus on inclusive planning reflects the growing global burden of the disease; since 1990, the total number of people living with diabetes—the majority of whom have type 2—has more than quadrupled, reaching 830 million in 2022. With over 40 percent of individuals currently unaware of their condition, the WHO emphasizes that early diagnosis remains a critical priority.